iScience (Nov 2021)
Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease
- Bryce M. Warner,
- Lisa A. Santry,
- Alexander Leacy,
- Mable Chan,
- Phuc H. Pham,
- Robert Vendramelli,
- Yanlong Pei,
- Nikesh Tailor,
- Emelissa Valcourt,
- Anders Leung,
- Shihua He,
- Bryan D. Griffin,
- Jonathan Audet,
- Marnie Willman,
- Kevin Tierney,
- Alixandra Albietz,
- Kathy L. Frost,
- Jacob G.E. Yates,
- Robert C. Mould,
- Lily Chan,
- Yeganeh Mehrani,
- Jason P. Knapp,
- Jessica A. Minott,
- Logan Banadyga,
- David Safronetz,
- Heidi Wood,
- Stephanie Booth,
- Pierre P. Major,
- Byram W. Bridle,
- Leonardo Susta,
- Darwyn Kobasa,
- Sarah K. Wootton
Affiliations
- Bryce M. Warner
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Lisa A. Santry
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Alexander Leacy
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Mable Chan
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Phuc H. Pham
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Robert Vendramelli
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Yanlong Pei
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Nikesh Tailor
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Emelissa Valcourt
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Anders Leung
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Shihua He
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Bryan D. Griffin
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Jonathan Audet
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Marnie Willman
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
- Kevin Tierney
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Alixandra Albietz
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Kathy L. Frost
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Jacob G.E. Yates
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Robert C. Mould
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Lily Chan
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Yeganeh Mehrani
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Jason P. Knapp
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Jessica A. Minott
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Logan Banadyga
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- David Safronetz
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
- Heidi Wood
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Stephanie Booth
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
- Pierre P. Major
- Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada
- Byram W. Bridle
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Leonardo Susta
- Department of Pathobiology, University of Guelph, Guelph, Canada
- Darwyn Kobasa
- Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
- Sarah K. Wootton
- Department of Pathobiology, University of Guelph, Guelph, Canada; Corresponding author
- Journal volume & issue
-
Vol. 24,
no. 11
p. 103219
Abstract
Summary: The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SARS-CoV-2-neutralizing antibody response, with elimination of infectious virus in the lungs and minimal lung pathology at five days post-challenge. Single-dose vaccination with NDV-FLS significantly reduced SARS-CoV-2 replication in the lungs but only mildly decreased lung inflammation. NDV-Δ19S-treated hamsters had a moderate decrease in SARS-CoV-2 titers in lungs and presented with severe microscopic lesions, suggesting that truncation of the spike protein was a less effective strategy. In summary, NDV-vectored vaccines represent a viable option for protection against COVID-19.
